Apnimed, Inc. operates as a clinical-stage company. The company is headquartered in Cambridge, Massachusetts. The firm's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
P/E (price / listing EPS) Forward revenue growth (NTM) 
